Teacher Retirement System of Texas Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Teacher Retirement System of Texas increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 902.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 288,250 shares of the medical device company's stock after acquiring an additional 259,491 shares during the period. Teacher Retirement System of Texas owned about 0.07% of DexCom worth $19,685,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of DXCM. Norges Bank acquired a new stake in DexCom in the 4th quarter valued at about $385,367,000. Woodline Partners LP acquired a new stake in DexCom in the 4th quarter valued at about $63,338,000. Northern Trust Corp raised its position in DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in DexCom in the 4th quarter valued at about $41,295,000. Finally, GAMMA Investing LLC raised its position in DexCom by 5,951.7% in the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock valued at $34,128,000 after purchasing an additional 491,488 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at $2,766,430.80. This represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

DXCM has been the topic of a number of analyst reports. Mizuho initiated coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Wall Street Zen lowered DexCom from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Citigroup reaffirmed a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and an average price target of $98.50.

DexCom Stock Performance

NASDAQ:DXCM traded down $0.85 during mid-day trading on Friday, reaching $82.73. 1,841,055 shares of the stock were exchanged, compared to its average volume of 4,413,224. The company has a 50 day simple moving average of $83.26 and a 200-day simple moving average of $79.82. The stock has a market capitalization of $32.44 billion, a P/E ratio of 61.74, a P/E/G ratio of 1.77 and a beta of 1.44. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 EPS. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.